Trump funding cuts may force Alzheimer’s disease study to shut down, affecting 600 aging adults

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-17T11:14:48.551Z • Permanent link

President Donald Trump's administration has made significant cuts to various research grants, including a notable $2.5 million grant for a study on Alzheimer's disease, set to close due to the lack of funds. This grant, initially approved in 2019, aimed to investigate the effects of environmental factors on the progression of the disease in two low-income, majority Black neighborhoods in Pittsburgh, Pennsylvania. Researchers from the University of Pittsburgh and the University of California, Los Angeles (UCLA) had been conducting the study since 2020, gathering crucial data on the impact of pollution and socioeconomic factors on the health of aging adults.

The study, led by Dr. Lisa Fitzpatrick, a renowned expert in environmental health and neuroscience, was one of several research initiatives funded by the National Institutes of Health (NIH) under the Trump administration. The grant, which was initially allocated $2.5 million over five years, aimed to recruit 600 aging adults from the affected neighborhoods and monitor their health over a period of 10 years. The researchers had made significant progress in collecting and analyzing data, but the grant's closure has left the study in jeopardy.

The decision to cut the grant is attributed to the Trump administration's broader efforts to reduce federal spending and reallocate resources to more "high-priority" research areas. While the NIH has not explicitly stated the reasons behind the grant's closure, experts speculate that the administration's priorities may have shifted towards more "conservative" and "market-driven" research initiatives.

The potential closure of the Alzheimer's disease study has significant implications for the research community, policymakers, and the affected communities. The study's findings, if published, could provide valuable insights into the impact of environmental factors on the progression of the disease, potentially informing the development of targeted interventions and public health policies. The loss of this research grant could also undermine the NIH's commitment to addressing health disparities and promoting diversity in the biomedical research workforce.

The closure of the grant may also have far-reaching consequences for the companies and organizations involved in the research, including pharmaceutical firms, medical device manufacturers, and research institutions. These stakeholders may need to adjust their strategies and allocate resources accordingly, potentially diverting attention and funding away from other research initiatives. Furthermore, the loss of this study's data could limit the ability of researchers to develop more effective treatments and interventions for Alzheimer's disease, a condition that affects millions of people worldwide.

The Trump administration's decision to cut research grants is part of a broader pattern of reducing federal funding for scientific research. Under the Trump administration, the NIH has faced significant budget constraints, leading to a decline in the number of research grants awarded and a reduction in the agency's overall budget. This trend has been echoed in other countries, including the United Kingdom, where the UK Research Council has faced significant funding cuts.